Reestablishment of p53/Arf and interferon-β pathways mediated by a novel adenoviral vector potentiates antiviral response and immunogenic cell death

Cell Death Discovery

Volumn 3, Issue , 2017, Pages

  Hunger, Aline ^a   Medrano, Ruan F V ^a   Zanatta, Daniela B ^a   Del Valle, Paulo R ^a   Merkel, Christian A ^a   Salles, Thiago de Almeida ^a   Ferrari, Daniel G ^b   Furuya, Tatiane K ^a   Bustos, Silvina O ^a   Saito, Renata de Freitas ^a   Costanzi Strauss, Eugenia ^a   Strauss, Bryan E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b MACKENZIE PRESBYTERIAN UNIVERSITY   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85019205213     PISSN: None     EISSN: 20587716     Source Type: Journal    
DOI: 10.1038/cddiscovery.2017.17     Document Type: Article

References (48)

1. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology 2009; 23: 488–496.
2. Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. Hum Mutat 2003; 21: 217–228.
3. Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, Houghton A et al. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 2001; 61: 7642–7646.
4. Sharpless E, Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003; 22: 3092–3098.
5. Jochemsen AG. Reactivation of p53 as therapeutic intervention for malignant melanoma. Curr Opin Oncol 2014; 26: 114–119.
6. Lu M, Miller P, Lu X. Restoring the tumour suppressive function of p53 as a parallel strategy in melanoma therapy. FEBS Lett 2014; 588: 2616–2621.
7. Lee B, Sandhu S, McArthur G. Cell cycle control as a promising target in melanoma. Curr Opin Oncol 2015; 27: 141–150.
8. Merkel CA, da Silva Soares RB, de Carvalho AC, Zanatta DB, Bajgelman MC, Fratini P et al. Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6. BMC Cancer 2010; 10: 316.
9. Sato M, Taniguchi T, Tanaka N. The interferon system and interferon regulatory factor transcription factors–studies from gene knockout mice. Cytokine Growth Factor Rev 2001; 12: 133–142.
10. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424: 516–523.
11. Munoz-Fontela C, Garcia MA, Garcia-Cao I, Collado M, Arroyo J, Esteban M et al. Resistance to viral infection of super p53 mice. Oncogene 2005; 24: 3059–3062.
12. Munoz-Fontela C, Macip S, Martinez-Sobrido L, Brown L, Ashour J, Garcia-Sastre A et al. Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med 2008; 205: 1929–1938.
13. Sandoval R, Xue J, Pilkinton M, Salvi D, Kiyokawa H, Colamonici OR. Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines. J Biol Chem 2004; 279: 32275–32280.
14. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51–72.
15. Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T et al. Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev 2013; 24: 311–318.
16. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S et al. Molecular mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 2014; 21: 79–91.
17. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P et al. Autophagy-dependent anticancer immune responses induced by chemother-apeutic agents in mice. Science 2011; 334: 1573–1577.
18. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20: 1301–1309.
19. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011; 208: 1989–2003.
20. Merkel CA, Medrano RF, Barauna VG, Strauss BE. Combined p19Arf and interferon-beta gene transfer enhances cell death of B16 melanoma in vitro and in vivo. Cancer Gene Ther 2013; 20: 317–325.
21. Medrano RF, Catani JP, Ribeiro AH, Tomaz SL, Merkel CA, Costanzi-Strauss E et al. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy. Cancer Immunol Immunother 2016; 65: 371–382.
22. Yamashita M, Ino A, Kawabata K, Sakurai F, Mizuguchi H. Expression of coxsackie and adenovirus receptor reduces the lung metastatic potential of murine tumor cells. Int J Cancer 2007; 121: 1690–1696.
23. Bajgelman MC, Strauss BE. Development of an adenoviral vector with robust expression driven by p53. Virology 2008; 371: 8–13.
24. Tamura RE, da Silva Soares RB, Costanzi-Strauss E, Strauss BE. Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy. Cancer Biol Ther 2016; 17: 1221–1230.
25. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844–848.
26. Núñez NG, Andreani V, Crespo MI, Nocera DA, Breser ML, Morón G et al. IFNβ produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer Res 2012; 72: 592–603.
27. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006; 126: 121–134.
28. Hasei J, Sasaki T, Tazawa H, Osaki S, Yamakawa Y, Kunisada T et al. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells. Mol Cancer Ther 2013; 12: 314–325.
29. Laforge M, Limou S, Harper F, Casartelli N, Rodrigues V, Silvestre R et al. DRAM triggers lysosomal membrane permeabilization and cell death in CD4(+) T cells infected with HIV. PLoS Pathog 2013; 9: e1003328.
30. Ke PY, Chen SS. Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. J Clin Invest 2011; 121: 37–56.
31. Kuenzel S, Till A, Winkler M, Hasler R, Lipinski S, Jung S et al. The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses. J Immunol 2010; 184: 1990–2000.
32. Ranjan P, Singh N, Kumar A, Neerincx A, Kremmer E, Cao W et al. NLRC5 interacts with RIG-I to induce a robust antiviral response against influenza virus infection. Eur J Immunol 2015; 45: 758–772.
33. Pitha-Rowe IF, Pitha PM. Viral defense, carcinogenesis and ISG15: novel roles for an old ISG. Cytokine Growth Factor Rev 2007; 18: 409–417.
34. Hummer BT, Li XL, Hassel BA. Role for p53 in gene induction by double-stranded RNA. J Virol 2001; 75: 7774–7777.
35. Huang Q, Li F, Liu X, Li W, Shi W, Liu FF et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 2011; 17: 860–866.
36. Vanden Berghe T, Hassannia B, Vandenabeele P. An outline of necrosome triggers. Cell Mol Life Sci 2016; 73: 2137–2152.
37. Upton JW, Kaiser WJ, Mocarski ES. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 2012; 11: 290–297.
38. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700–714.
39. Yang H, Ma Y, Chen G, Zhou H, Yamazaki T, Klein C et al. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoim-munology 2016; 5: e1149673.
40. Okumura A, Pitha PM, Harty RN. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc Natl Acad Sci USA 2008; 105: 3974–3979.
41. Okumura A, Lu G, Pitha-Rowe I, Pitha PM. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc Natl Acad Sci USA 2006; 103: 1440–1445.
42. Thaci B, Ulasov IV, Wainwright DA, Lesniak MS. The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget 2011; 2: 113–121.
43. Takaoka A, Wang Z, Choi MK, Yanai H, Negishi H, Ban T et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007; 448: 501–505.
44. Muruve DA, Pétrilli V, Zaiss AK, White LR, Clark SA, Ross PJ et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008; 452: 103–107.
45. Mizuguchi H, Koizumi N, Hosono T, Utoguchi N, Watanabe Y, Kay MA et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 2001; 8: 730–735.
46. Ghattas IR, Sanes JR, Majors JE. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol 1991; 11: 5848–5859.
47. Catani JP, Medrano RF, Hunger A, Del Valle P, Adjemian S, Zanatta DB et al. Intratumoral immunization by p19Arf and interferon-beta gene transfer in a heterotopic mouse model of lung carcinoma. Transl Oncol 2016; 9: 565–574.
48. Peng HH, Wu S, Davis JJ, Wang L, Roth JA, Marini FC 3rd et al. A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers. Anal Biochem 2006; 354: 140–147.